SCHEMBL30339882

SCHEMBL30339882

Cc1cn(-c2cc(NC(=O)c3ccc(C)c(CNC(=O)c4cnc5[nH]ccc5c4)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.66
▸ MAP3K20 Q9NYL2 1/20 0.66
▸ MAP3K7 O43318 1/20 0.58
▸ MAP4K2 Q12851 1/20 0.58
▸ NR2E1 Q9Y466 2/20 0.56
▸ LDLR P01130 1/20 0.56
▸ KIT P10721 1/20 0.56
▸ PCSK9 Q8NBP7 1/20 0.56
▸ ABL1 P00519 11/20 0.55
▸ BCR P11274 10/20 0.55
▸ EPHB2 P29323 1/20 0.54
▸ HCK P08631 2/20 0.54
▸ NR2C2 P49116 1/20 0.54
▸ BTK Q06187 1/20 0.54
▸ NR1I2 O75469 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ KDR P35968 1/20 0.52
▸ CHRNA4 P43681 1/20 0.52
▸ PDE3A Q14432 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24070473 1.00 MAPK14 (0.66) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL30447296 0.90 MAPK14 (0.69) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL24070682 0.90 MAPK14 (0.69) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL4789491 0.89 ABL1 (0.69) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL3424818 0.84 MAPK14 (0.62) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL4788636 0.82 EPHB2 (0.59) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL29514885 0.81 ABL1 (0.78) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL14953321 0.81 ABL1 (0.78) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL4788638 0.81 CSF1R (0.69) MAPK14MAP3K20MAP3K7MAP4K2NR2E1
SCHEMBL24070548 0.81 NR2E1 (0.69) MAPK14MAP3K20MAP3K7MAP4K2NR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US disclosed
EP-4157447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS DDR2, DDR1, DDRGK1 MAPK14 2850/4885MAP3K20 459/4885MAP3K7 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback